Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer

BACKGROUND: A 21-gene recurrence score (RS) assay may inform adjuvant systematic treatment decisions in women with early stage breast cancer. We sought to investigate the cost effectiveness of using the RS-assay versus current clinical practice (CCP) in women with early-stage estrogen- or progestero...

Descripción completa

Detalles Bibliográficos
Autores principales: Hannouf, Malek B, Xie, Bin, Brackstone, Muriel, Zaric, Gregory S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488327/
https://www.ncbi.nlm.nih.gov/pubmed/23031196
http://dx.doi.org/10.1186/1471-2407-12-447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488327/
https://www.ncbi.nlm.nih.gov/pubmed/23031196
http://dx.doi.org/10.1186/1471-2407-12-447

Ejemplares similares